Cordis eyes vascular closure market with US trial for ExoSeal device:
This article was originally published in Clinica
Executive Summary
As part of efforts to enter the vascular closure device market, Cordis has begun a pivotal US trial of its ExoSeal product for closing punctures in patients undergoing catheterisation procedures. The trial, called ECLIPSE, will assess the safety and efficacy of ExoSeal versus manual compression, as a means of closing vascular access sites in patients who have undergone diagnostic or interventional procedures. It is a non-blinded, randomised study that will encompass 400 patients from 18 medical centres. ExoSeal features a synthetic bioabsorbable polymer and is being studied to determine whether it can enable expedited the cessation of bleeding, faster patient ambulation and reduced bed-stay. Nearly eight million patients undergo cardiac catheterisation procedures annually, said Cordis, a Johnson & Johnson company.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.